Boehringer's Vargate enters Ph III NSCLC trials

8 December 2008

Germany's Boehringer Ingelheim has progressed another of its oncology compounds into pivotal Phase III development. Two studies, known as LUME-Lung 1 and LUME-Lung 2, will assess its triple angiokinase inhibitor Vargate (BIBF 1120) as a second-line therapy in combination with standard chemotherapy agents in advanced, non-small cell lung cancer.

The company's cancer portfolio spans three key areas of focus: angiokinase inhibition, signal transduction inhibition and cell cycle kinase inhibition. In addition, Boehringer's most advanced compound Tovok (BIBW 2992) will soon enter its second pivotal trial, LUX-Lung 3, in first-line NSCLC.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Companies featured in this story

More ones to watch >






Company Spotlight